[IOICORP] YoY Quarter Result on 31-Dec-2013 [#2]

Stock
[IOICORP] IOI CORPORATION BHD
Announcement Date
25-Feb-2014
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2014
Quarter
31-Dec-2013 [#2]
Profit Trend
QoQ- 61.4%
YoY- -8.27%
Quarter Report
Latest QR
Upcoming QR
IOICORP's Result
IOICORP's Financial Summary
View:
Show?
Quarter Result
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
Revenue 2,506,500 2,968,500 2,857,200 2,939,400 3,252,000 4,165,900 3,970,487 -7.37%
PBT 52,500 876,500 94,600 487,300 490,300 766,800 689,324 -34.86%
Tax -25,900 -139,700 -69,000 7,000 50,000 -174,700 -135,593 -24.09%
NP 26,600 736,800 25,600 494,300 540,300 592,100 553,731 -39.67%
-
NP to SH 15,600 724,800 19,600 487,100 531,000 577,700 520,238 -44.23%
-
Tax Rate 49.33% 15.94% 72.94% -1.44% -10.20% 22.78% 19.67% -
Total Cost 2,479,900 2,231,700 2,831,600 2,445,100 2,711,700 3,573,800 3,416,756 -5.19%
-
Net Worth 7,168,433 4,785,820 5,437,419 4,474,671 13,163,175 12,144,648 11,043,089 -6.94%
Dividend
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
Div 282,964 220,399 284,516 511,391 447,292 449,801 510,663 -9.36%
Div Payout % 1,813.88% 30.41% 1,451.61% 104.99% 84.24% 77.86% 98.16% -
Equity
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
Net Worth 7,168,433 4,785,820 5,437,419 4,474,671 13,163,175 12,144,648 11,043,089 -6.94%
NOSH 6,461,000 6,297,132 6,322,580 6,392,388 6,389,891 6,425,739 6,383,288 0.20%
Ratio Analysis
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
NP Margin 1.06% 24.82% 0.90% 16.82% 16.61% 14.21% 13.95% -
ROE 0.22% 15.14% 0.36% 10.89% 4.03% 4.76% 4.71% -
Per Share
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
RPS 39.86 47.14 45.19 45.98 50.89 64.83 62.20 -7.14%
EPS 0.25 11.51 0.31 7.62 8.31 8.99 8.15 -44.02%
DPS 4.50 3.50 4.50 8.00 7.00 7.00 8.00 -9.13%
NAPS 1.14 0.76 0.86 0.70 2.06 1.89 1.73 -6.70%
Adjusted Per Share Value based on latest NOSH - 6,392,388
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
RPS 40.05 47.43 45.66 46.97 51.96 66.57 63.45 -7.37%
EPS 0.25 11.58 0.31 7.78 8.49 9.23 8.31 -44.20%
DPS 4.52 3.52 4.55 8.17 7.15 7.19 8.16 -9.36%
NAPS 1.1455 0.7647 0.8689 0.715 2.1034 1.9406 1.7646 -6.94%
Price Multiplier on Financial Quarter End Date
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
Date 30/12/16 31/12/15 31/12/14 31/12/13 31/12/12 30/12/11 30/12/10 -
Price 4.40 4.46 4.80 4.71 5.10 5.38 5.81 -
P/RPS 11.04 9.46 10.62 10.24 10.02 8.30 9.34 2.82%
P/EPS 1,773.57 38.75 1,548.39 61.81 61.37 59.84 71.29 70.77%
EY 0.06 2.58 0.06 1.62 1.63 1.67 1.40 -40.81%
DY 1.02 0.78 0.94 1.70 1.37 1.30 1.38 -4.90%
P/NAPS 3.86 5.87 5.58 6.73 2.48 2.85 3.36 2.33%
Price Multiplier on Announcement Date
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
Date 20/02/17 19/02/16 13/02/15 25/02/14 21/02/13 23/02/12 16/02/11 -
Price 4.63 4.75 4.81 4.73 4.90 5.33 5.71 -
P/RPS 11.62 10.08 10.64 10.29 9.63 8.22 9.18 4.00%
P/EPS 1,866.28 41.27 1,551.61 62.07 58.97 59.29 70.06 72.72%
EY 0.05 2.42 0.06 1.61 1.70 1.69 1.43 -42.78%
DY 0.97 0.74 0.94 1.69 1.43 1.31 1.40 -5.92%
P/NAPS 4.06 6.25 5.59 6.76 2.38 2.82 3.30 3.51%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment